Costs of Study. The Parties agree that: (a) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below; (b) each Party will be responsible for its own internal costs and expenses to support the Study and the costs of any Sample Testing conducted by such Party in connection with the Study; and (c) Company shall bear all other costs associated with the conduct of the Study, including that Company shall provide the Company Compound for use in the Study, as described in Article 8 below. For the avoidance of doubt, Company will not be required to reimburse Merck for any costs or expenses incurred by Merck or its Affiliates in connection with the Study (except as provided in Section 6.11) and Merck will not be required to reimburse Company for any costs or expenses incurred by Company or its Affiliates in connection with the Study (except as provided in Section 6.11).
Costs of Study. The Parties agree that: [***].
Costs of Study. The Parties agree that (i) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below; (ii) each Party will be responsible for its own internal costs and expenses to support the Study and the costs of any Sample Testing conducted by such Party in connection with the Study, and (iii) BioLineRx shall bear all other costs associated with the conduct of the Study, including that BioLineRx shall provide the BioLineRx Compound for use in the Study, as described in Article 8 below. For the avoidance of doubt, BioLineRx will not be required to reimburse Merck for any costs or expenses incurred by Merck or its Affiliates in connection with the Study and Merck will not be required to reimburse BioLineRx for any costs or expenses incurred by BioLineRx or its Affiliates in connection with the Study.
Costs of Study. The Parties agree that: (a) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below; (b) each Party will be responsible for its own internal costs and expenses to support the Study and the costs of any Sample Testing conducted by such Party in connection with the Study; and (c) Antigen Express shall bear all other costs associated with the conduct of the Study, including that Antigen Express shall provide the Antigen Express Compound for use in the Study, as described in Article 8 below. For the avoidance of doubt, Antigen Express will not be required to reimburse Merck for any costs or expenses incurred by Merck or its Affiliates in connection with the Study (except as provided in Section 6.11) and Merck will not be required to reimburse Antigen Express for any costs or expenses incurred by Antigen Express or its Affiliates in connection with the Study.
Costs of Study. The Parties agree that (i) Pfizer shall provide the Pfizer Compound for use in the Study, as described in Article 8 below, at no cost to Ideaya (except as provided in Section 6.11); and (ii) Ideaya shall provide the Ideaya Compound for use in the Study, as described in Article 8 below, at no cost to Pfizer. The Study costs will be paid fully by Ideaya.
Costs of Study. The Parties agree that: (a) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below at *** ; (b) each Party will be responsible for its own internal costs and expenses to support the Study and the costs of any Sample Testing conducted by such Party in connection with the Study; and (c) Adaptimmune shall bear all other costs associated with the conduct of the Study, including that Adaptimmune shall provide the Adaptimmune Compound for use in the Study, as described in Article 8 below. For the avoidance of doubt, Adaptimmune will not be required to reimburse Merck for any costs or expenses *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. incurred by Merck or its Affiliates in connection with the Study (except as provided in Section 6.11) and Merck will not be required to reimburse Adaptimmune for any costs or expenses incurred by Adaptimmune or its Affiliates in connection with the Study.
Costs of Study. 7.1 The Parties agree that (i) Merck shall provide Merck Compound for use in the Study, as described in Article 8 below, at no cost to Vaccinex; and (ii) Vaccinex shall provide the Vaccinex Compound for use in the Study, as described in Article 8 below, at no cost to Merck. The Study Costs set forth in the Study Budget will be [***] by Vaccinex and Merck up to a maximum of US$[***] in Study Costs (the “Study Costs Reimbursement Cap”), with Merck reimbursing [***]% of all such Study Costs incurred, up to [***]% of the Study Costs Reimbursement Cap, on a Calendar Quarter basis, as set forth in this Article 7. A good faith estimate of the total expected Study Costs as of the Effective Date is attached hereto as Appendix C (the “Study Budget”), which Study Budget may be amended from time to time by mutual agreement of the JCSC or the Parties. Within [***] of the end of each Calendar Quarter Vaccinex shall provide Merck an invoice, in reasonable detail, setting forth the incurred Study Costs, on the basis of the estimated Study Costs for such Calendar Quarter. Within [***] following receipt of each such invoice by Merck, Merck shall reimburse Vaccinex for [***]% of [***] INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. Note: Reference to “Merck” in this document refers to the Group of Companies affiliated with Merck KGaA, Darmstadt, Germany. the total Study Costs incurred by Vaccinex during such Calendar Quarter. Concurrently with each such Calendar Quarter invoice, Vaccinex shall describe in writing any material deviations in the Study Costs from the original estimate that represent an aggregate increase or decrease of more than [***] between the actual Study Costs incurred and the estimated Study Costs for such Calendar Quarter as set forth in the Study Budget. Provided that the Parties have agreed to such deviations of more than [***] in a JCSC meeting, Merck shall pay [***]% of any such additional costs and the original Study Costs estimate shall be adjusted accordingly (i.e., an aggregate increase or decrease of more than [***] between the actual Study Costs incurred and the estimated Study Costs for such Calendar Quarter as set forth in the Study Budget. For clarity, [***].
Costs of Study. The Parties agree that: (a) Merck shall provide the Merck Compound for use in the Study, as described in Article 8 below; (b) [***]; and (c) Rexahn shall bear[***]other costs associated with the conduct of the Study[***].
Costs of Study. [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. The Parties agree that (i) Pfizer shall provide the Pfizer Compound for use in the Study, as described in Article 8 below, at no cost to Ideaya (except as provided in Section 6.11); and (ii) Ideaya shall provide the Ideaya Compound for use in the Study, as described in Article 8 below, at no cost to Pfizer. The Study costs will be paid fully by Ideaya.
Costs of Study. 7.1 Except as expressly set forth herein, the Parties will equally share the Direct Costs of the Study to the extent consistent with the budget set forth in the Development Plan; provided that each Party shall be responsible for its own internal costs and expenses to support the Study. Within [***] days after the end of each calendar quarter during the Term, Amgen will prepare a detailed accounting of the total Direct Costs during such Calendar quarter and shall send a copy of such accounting to Ideaya; provided, however, that a preliminary estimate of such Direct Costs shall be provided by Amgen to Ideaya as promptly as practicable following the end of each calendar quarter. Amgen shall determine (within [***] days thereafter) the appropriate reimbursement from Ideaya so that the total Direct Costs for the quarter are shared equally by the Parties, and such reimbursement shall be made by Ideaya within [***] days of such determination and receipt of a respective Invoice; provided that if Amgen submits an accounting for Direct Costs that materially (greater than [***] deviation) exceeds Amgen’s estimated Direct Costs set forth in the Development Plan for the applicable activities or tasks under the Development Plan, then the Parties shall discuss in good faith such cost overrun, and Ideaya shall not be required to bear its 50% share of the overrun except on good cause shown by Amgen (or as otherwise agreed by the JOC).
